From: Cancer vaccines as promising immuno-therapeutics: platforms and current progress
NCT number | Targeted antigens/biological | Results | Phases |
---|---|---|---|
NCT01302496 | CD70, CD40 ligand, tyrosinase, gp100, MAGE-A3, or MAGE-C2 | After more than five years, TriMixDC-MEL ipilimumab treatment resulted in median overall survival of 28% and a median progression-free survival of 18%. After a median follow-up of 390Â weeks, 11 /39 patients are alive of whom seven remain free-from progression and have remained in complete remission following treatment with TriMIxDC-MEL ipilimumab | II |
NCT02139267 | HPV | 52% (33/64) of patients at per-protocol analysis and 67% (35/52) of patients at extension analysis presented histopathologic regression after receiving the GX-188E injection. 73% (per-protocol study) and 77% (extension analysis) of the patients with histologic regression showed HPV clearance | II |
NCT03481816 | PSA, brachyury, MUC1 | The primary endpoints were met and there were no DLTs. Seventeen of 17(100%) patients mounted T-cell responses to at least one TAA, whereas 8 (47%) of 17 patients mounted immune responses to all three TAAs | I |
NCT03384316 | MUC1, CEA | The vaccine was generally well-tolerated. Antigen-specific T cells to MUC1, CEA, and brachyury were generated in all patients (Ten patients enrolled on trial) | I |
NCT03199872 | RV001V | The vaccine was generally well-tolerated, Targeting of RhoC induced a potent and long-lasting T cell immunity in the majority of the patients (18 of 21 evaluable) | I/II |
NCT02981524 | GVAX | Seventeen patients were enrolled. Grade ≥ 3 treatment-related adverse events were observed in two patients. There were no objective responses, and the disease control rate was 18% by RECIST 1.1. Biochemical responses (≥ 30% decline in CEA) were observed in 7/17 (41%) of patients | II |
NCT02179515 | MVA-brachyury- TRICOM | One transient grade 3 adverse event occurs. Including all DLs and all cancer types, 28/34 (82%) patients developed brachyury-specific CD4 + and/or CD8 + T-cell responses after vaccination | I |
NCT02153918 | PROSTVAC-V/F | The treatment course was well-tolerated, with no serious adverse events (AEs) or toxicities > grade 2 attributed to the vaccine. A total of 13/25 patients (52%) developed peripheral T-cell responses to any of the three tested TAAs (non-neoantigens) | II |
NCT02004262 | GVAX, CRS-207 | All treatments were generally well-tolerated. The study did not meet its primary efficacy endpoint. The combination of Cy/GVAX + CRS-207 did not improve survival over chemotherapy | II |
NCT01876212 | TBVA | All treatments were generally well-tolerated. 6 patients (13 evaluable patients) developed specific peripheral blood T cell responses against ≥ 3 vaccine-associated peptides, with further evidence of epitope spreading | II |
NCT01867086 | GMCSF, TGFβ | There were no treatment-related serious adverse events. FANG vaccine elicited an immune response correlating with prolonged survival | II |
NCT01706458 | PAP | The treatment course was well-tolerated, with no serious adverse events (AEs) or toxicities > grade 2 attributed to the vaccine. Median time to progression was less than 6 months and not statistically different between study arms. Th1-biased PAP-specific T-cell responses were detected in 11 individuals (completed treatments) and were not statistically different between study arms | II |
NCT01570036 | HER2 | 275 patients were randomized, there were no clinicopathologic differences between vaccine and control group | II |
NCT01519817 | Brachyury | The treatment was well-tolerated, with no DLTs. 17/31 (54%) (including all dose levels) of patients developed brachyury-specific CD4 and/or CD8 T-cell responses post-vaccination | I |
NCT01417000 | GVAX, CRS-207 | The treatment was well-tolerated. Heterologous prime/boost with Cy/GVAX and CRS-207 extended survival for patients with pancreatic cancer | II |
NCT01341652 | PAP | Two-year metastasis-free survival was not different between study arms (41.8% vaccine v 42.3%; P = .97) | II |
NCT00088413 | MUC-1, CEA | Some patients who had limited tumor burden with minimal prior chemotherapy seemed to benefit from the vaccine | I/II |